N-butyldeoxygalactonojirimycin: A more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo

Biochemical Pharmacology

Volumn 59, Issue 7, 2000, Pages 821-829

  Andersson, Ulrika ^a   Butters, Terry D ^a   Dwek, Raymond A ^a   Platt, Frances M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Glycosphingolipid; Glycosphingolipid lysosomal storage diseases; Iimino sugars; Inhibitors; N butyldeoxygalactonojirimycin; N butyldeoxynojirimycin

Indexed keywords

ALPHA GLUCOSIDASE; CERAMIDE GLUCOSYLTRANSFERASE; GLYCOSPHINGOLIPID; LACTASE; MIGLUSTAT; SUCRASE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FABRY DISEASE; GAUCHER DISEASE; GLYCOGENOLYSIS; IN VITRO STUDY; LIVER; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL;

1-DEOXYNOJIRIMYCIN; ANIMALS; CARBON RADIOISOTOPES; CELL DIVISION; DISACCHARIDASES; ENZYME INHIBITORS; FEMALE; GLYCOGEN; GLYCOSPHINGOLIPIDS; HUMANS; LIVER; LYMPHOCYTES; MICE; MICE, INBRED C57BL; TISSUE DISTRIBUTION;

EID: 0033952264     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00384-6     Document Type: Article

References (24)

1. Neufeld E.F. Lysosomal storage diseases. Annu Rev Biochem. 60:1991;257-280.
2. Platt F.M., Butters T.D. New therapeutic prospects for the glycosphingolipid lysosomal storage diseases. Biochem Pharmacol. 56:1998;421-430.
3. Radin N.S. Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J. 13:1996;153-157.
4. Salvetti A., Heard J.M., Danos O. Gene therapy of lysosomal storage disorders. Br Med Bull. 51:1995;106-122.
5. Erikson A., Groth C.G., Mansson J.E., Percy A., Ringden O., Svennerholm L. Clinical and biochemical outcome of marrow transplantation for Gaucher disease of the Norrbottnian type. Acta Paediatr Scand. 79:1990;680-685.
6. Ringden O., Groth C.G., Erikson A., Granqvist S., Mansson J.E., Sparrelid E. Ten years' experience of bone marrow transplantation for Gaucher disease. Transplantation. 59:1995;864-870.
7. Barton N.W., Furbish F.S., Murray G.J., Garfield M., Brady R.O. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA. 87:1990;1913-1916.
8. Cox T.M. Therapeutic advances in Gaucher's disease a model for the treatment of lysosomal storage diseases . Trends Exp Clin Med. 4:1994;144-160.
9. Grabowski G.A., Barton N.W., Pastores G., Dambrosia J.M., Banerjee T.K., McKee M.A., Parker C., Schiffmann R., Hill S.C., Brady R.O. Enzyme therapy in type 1 Gaucher disease Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources . Ann Intern Med. 122:1995;33-39.
10. Beutler E. Gaucher disease New molecular approaches to diagnosis and treatment . Science. 256:1992;794-799.
11. Beutler E. Gaucher disease as a paradigm of current issues regarding single gene mutations of humans. Proc Natl Acad Sci USA. 90:1993;5384-5390.
12. Platt F.M., Butters T.D. Inhibitors of glycosphingolipid biosynthesis. Trends Glycosci Glycotechnol. 7:1995;495-511.
13. Platt F.M., Neises G.R., Dwek R.A., Butters T.D. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem. 269:1994;8362-8365.
14. Platt F.M., Reinkensmeier G., Dwek R.A., Butters T.D. Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem. 272:1997;19365-19372.
15. Platt F.M., Neises G.R., Reinkensmeier G., Townsend M.J., Perry V.H., Proia R.L., Winchester B., Dwek R.A., Butters T.D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science. 276:1997;428-431.
16. Jeyakumar M., Butters T.D., Cortina-Borja M., Junnam V., Proia R.L., Perry V.H., Dwek R.A., Platt F.M. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin. Proc Natl Acad Sci USA. 96:1999;6388-6393.
17. Winchester B., Fleet G.W. Amino-sugar glycosidase inhibitors Versatile tools for glycobiologists . Glycobiology. 2:1992;199-210.
18. 3. J Acquir Immune Defic Syndr. 7:1994;139-147.
19. Platt F.M., Neises G.R., Karlsson G.B., Dwek R.A., Butters T.D. N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem. 269:1994;27108-27114.
20. Leighton B., Blomstrand E., Challiss R.A., Lozeman F.J., Parry-Billings M., Dimitriadis G.D., Newsholme E.A. Acute and chronic effects of strenuous exercise on glucose metabolism in isolated, incubated soleus muscle of exercise-trained rats. Acta Physiol Scand. 136:1989;177-184.
21. Hanozet G., Pircher H.P., Vanni P., Oesch B., Semenza G. An example of enzyme hysteresis. The slow and tight interaction of some fully competitive inhibitors with small intestinal sucrase. J Biol Chem. 256:1981;3703-3711.
22. Arai M., Minatoguchi S., Akemura G., Uno Y., Kariya T., Takatsu H., Fujiwara T., Higashioka M., Yoshikuni Y., Fujiwara H. N-methyl-1-deoxynojirimycin (MOR-14), an alpha-glucosidase inhibitor, markedly reduced infarct size in rabbit hearts. Circulation. 97:1998;1290-1297.
23. Bollen M., Stalmans W. The antiglycogenolytic action of 1-deoxynojirimycin results from a specific inhibition of the alpha-1,6-glucosidase activity of the debranching enzyme. Eur J Biochem. 181:1989;775-780.
24. Hollak C.E., van Weely S., van Oers M.H., Aerts J.M. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest. 93:1994;1288-1292.